Boyds is delighted to announce the appointment of regulatory expert in the pharma, biotech and medical devices sectors, Eamonn McGowran, as Associate Director.
Based at Boyds’ Irish operation at Talent Garden Dublin, Eamonn’s appointment marks the beginning of the next phase of growth and expansion in Dublin and Europe for Boyds, which will harness his leading and specialist regulatory experience in medical devices to boost and enhance its comprehensive regulatory advice and services portfolio.
Boyds’ Dublin office represents the consultancy’s gateway to Europe and supports its close work with the European Medicines Agency (EMA) that is central to its high-level development of medicines for patient benefit.
Eamonn McGowran is the latest of 20 new starters since March, which includes key hires in new roles that further enhance Boyds’ expertise and expand the business, in response to a 25 percent surge in turnover and sustained growth in demand for its services across the UK, Europe and the US.
A graduate of Dublin City University with a BSc in Biotechnology and an MSc in Plant Biotechnology, Eamonn has over 20 years’ experience in the pharmaceutical, biopharmaceutical, medical device, food and cosmetic sectors.
Previously Head of Quality and Regulatory Affairs at Dublin-based Kora Healthcare, Eamonn has also held senior pharmaceutical and biotech regulatory affairs roles at Klox Technologies Ireland, Norigen Consulting Dublin, It Works! Quintiles, and ICON.
“It is significant to Boyds’ plans to have Eamonn and in particular his regulatory experience in medical devices as part of the growing team,” says Dr Julie Warner, Vice President of Regulatory Affairs at Boyds. “Expanding the Dublin operation and growing the team based here is central to our 2022 expansion strategy, which will enhance the support provided to our European and global clients.”
Of joining Boyds, Eamonn says: “The areas in which the Boyds team is operating are on the cutting edge of medical development. Personally, this is one of those rare opportunities that gives me the chance to fully utilise my experience and harness my knowledge of global regulatory and quality needs, to enable access to markets for both large and small pharma, medical device and biotech organisations.”
Eamonn McGowran is currently undertaking a part-time PhD in TU Dublin, exploring the early adoption of regulatory science in the drug development lifecycle.
